The study reviews the influence of KRAS, NRAS, BRAF mutations, and MSI in non-metastatic colon cancer. MSI-H is present in 15% of cases and generally predicts better outcomes than microsatellite stable (MSS) cancers. However, KRAS and BRAF mutations, typically associated with poor prognosis in MSS, show a less pronounced negative impact in MSI-H cancers, mainly affecting outcomes post-recurrence rather than immediate disease-free survival. These findings emphasize the importance of genetic profiling in clinical decision-making to optimize therapeutic strategies for colon cancer patients.
Read more: https://doi.org/10.3390/diagnostics14101001
Get free health updates from Dr Harsh Shah on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
Leave a Reply